Latest Patents News

Way2VAT has restructured its debt with Bank Hapoalim, securing a larger $4.876 million facility and extending loan terms to three years to support growth and approach breakeven.

ClearVue Technologies is inviting eligible shareholders to participate in a $1 million Share Purchase Plan at a discount, following a $5 million institutional placement. The capital raised will support ERP rollout, R&D, and working capital.

Calix's subsidiary Leilac has locked in a paid engineering study with an East Asian cement producer, advancing its commercial cement decarbonisation technology without capital outlay. This complements its recent Indian partnership and signals a strategic pivot to capital-light projects.

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.

Orcoda has secured a lucrative multi-year contract with Wagner Corporation to deliver workforce logistics and facilities management at Wellcamp Business Park, leveraging its AI-driven Contractor360 platform.

Tasmea Limited is set to acquire JPS Group for up to A$75 million, securing a foothold in Australia’s growing LNG and energy infrastructure sectors with a Tier-1 client base and a unique tech-enabled isolation technology.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

Identitii is contesting JPMorgan Chase’s motion seeking a $4 million attorneys’ fee award in their ongoing US patent dispute, while continuing its appeal against case dismissal.

ClearVue Technologies has boosted its capital raising to $6.25 million, with significant board participation and revised loan terms, while its Gen 3 Vision Glass secures crucial EN 1279-5 certification.

Osteopore Limited has completed another incremental drawdown of A$250,000 on the second tranche of its redeemable convertible notes, continuing its steady funding progress under a A$20 million subscription agreement with Advance Opportunities Fund.